Summary of Product Characteristics (SmPC) - Carbidopa/levodopa 10 mg/100 mg tablets
1 NAME OF THE MEDICINAL PRODUCT
Carbidopa/Levodopa 10 mg/100 mg tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 10.8 mg carbidopa monohydrate (equivalent to 10 mg carbidopa) and 100 mg levodopa.
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablets
Blue to Light blue, round shaped, approximately 8 mm, uncoated scored tablets debossed with ‘CA’ and ‘10’ separated by score line on one side and ‘LT 100’on the other side. The tablet can be divided into equal doses.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
For the treatment of Parkinson's disease and syndrome
4.2 Posology and method of administration
Posology
The optimum daily dosage of Carbidopa/Levodopa must be determined by careful titration in each patient.
Carbidopa/Levodopa Tablets are available in a ratio of 1:4 or 1:10 of carbidopa to levodopa to provide facility for fine dosage titration for each patient.
General Considerations
Studies show that the peripheral dopa-decarboxylase is fully inhibited (saturated) by carbidopa at doses between 70 and 100 mg a day. Patients receiving less than this amount of carbidopa are more likely to experience nausea and vomiting.
Standard antiparkinsonian drugs, other than levodopa alone, may be continued while Carbidopa/Levodopa tablet is being administered, although their dosage may have to be adjusted.
Because both therapeutic and adverse effects are seen more rapidly with Carbidopa/Levodopa tablet than with levodopa, patients should be carefully monitored during the dosage adjustment period. Involuntary movements, particularly blepharospasm, are a useful early sign of excess dosage in some patients.
Patients not receiving levodopa
Dosage may be best initiated with one tablet of Carbidopa/Levodopa tablet 25 mg/100 mg three times a day. This dosage schedule provides 75 mg of carbidopa per day. Dosage may be increased by one tablet of Carbidopa/Levodopa 12.5 mg/50 mg' or Carbidopa/Levodopa tablet 25 mg/100 mg' every day or every other day, as necessary, until a dosage equivalent of eight tablets of Carbidopa/Levodopa tablet 25 mg/100 mg' a day is reached.
If Carbidopa/Levodopa 10 mg/100 mg Tablets' or Carbidopa/Levodopa 12.5 mg/50 mg Tablets' are used, dosage may be initiated with one tablet three or four times a day. Titration upward may be required in some patients to achieve optimum dosage of carbidopa. The dosage may be increased by one tablet every day or every other day until a total of eight tablets (two tablets q.d.s.) is reached.
Response has been observed in one day, and sometimes after one dose. Fully effective doses usually are reached within seven days as compared to weeks or months with levodopa alone.
Carbidopa/Levodopa 12.5 mg/50 mg Tablets' or Carbidopa/Levodopa 10 mg/100 mg tablet may be used to facilitate dosage titration according to the needs of the individual patient.
Patients receiving levodopa
Discontinue levodopa at least 12 hours (24 hours for slow-release preparations) before starting therapy with Carbidopa/Levodopa tablet. The easiest way to do this is to give Carbidopa/Levodopa tablet as the first morning dose after a night without any levodopa. The dose of Carbidopa/Levodopa tablet should be approximately 20% of the previous daily dosage of levodopa.
Patients taking less than 1,500 mg levodopa a day should be started on one tablet of Carbidopa/Levodopa 25 mg/100 mg' three or four times a day dependent on patient need. The suggested starting dose for most patients taking more than 1,500 mg levodopa a day is one tablet of Carbidopa/Levodopa 25 mg/250 mg' three or four times a day.
Maintenance
Therapy with Carbidopa/Levodopa tablet should be individualised and adjusted gradually according to response. When a greater proportion of carbidopa is required, each tablet of Carbidopa/Levodopa tablet 10 mg/100 mg may be replaced with a tablet of Carbidopa/Levodopa 25 mg/100 mg' or Carbidopa/Levodopa 12.5 mg/50 mg'.
When more levodopa is required, Carbidopa/Levodopa 25 mg/250 mg Tablets should be substituted at a dosage of one tablet three or four times a day. If necessary, the dosage of Carbidopa/Levodopa 25 mg/250 mg Tablets' may be increased by one tablet every day or every other day to a maximum of eight tablets a day. Experience with a total daily dosage greater than 200 mg carbidopa is limited.
Patients receiving levodopa with another decarboxylase inhibitor
When transferring a patient to Carbidopa/Levodopa tablet from levodopa combined with another decarboxylase inhibitor, discontinue dosage at least 12 hours before Carbidopa/Levodopa tablet is started. Begin with a dosage of Carbidopa/Levodopa tablet that will provide the same amount of levodopa as contained in the other levodopa/decarboxylase inhibitor combination.
Patients receiving other antiparkinsonian agents
Current evidence indicates that other antiparkinsonian agents may be continued when Carbidopa/Levodopa tablet is introduced, although dosage may have to be adjusted in line with manufacturers recommendations.
Paediatric population
The safety and efficacy of Carbidopa/Levodopa tablet in children under 18 years of age has not been established and its use in patients below the age of 18 is not recommended.
Elderly
There is wide experience in the use of this product in elderly patients. The recommendations set out above reflect the clinical data derived from this experience.
Method of administration
For oral use.
If a tablet breaks when it is removed from the packaging, it should only be consumed if the whole dose can be taken. If it cannot, the pieces of the broken tablet should be discarded and another tablet taken from the packaging.
Administration of a partial dose may result in worsening of symptoms.
4.3 Contraindications
Non-selective monoamine oxidase (MAO) inhibitors are contraindicated for use with Carbidopa/Levodopa tablet. These inhibitors must be discontinued at least two weeks before starting Carbidopa/Levodopa tablet. Carbidopa/Levodopa tablet may be administered concomitantly with the manufacturer’s recommended dose of an MAO inhibitor with selectivity for MAO type B (e.g. selegiline hydrochloride). (See section 4.5 'Interaction with other medicinal products and other forms of interaction'.)
Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1.
Carbidopa/Levodopa tablet is contraindicated in patients with narrow-angle glaucoma.
Since levodopa may activate a malignant melanoma, it should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma. Use in patients with severe psychoses.
See also section 4.6 'Fertility, pregnancy and lactation'.
4.4 Special warnings and precautions for use
Carbidopa/Levodopa tablet is not recommended for the treatment of drug-induced extrapyramidal reactions.
Carbidopa/Levodopa tablet should be administered cautiously to patients with severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease, or history of peptic ulcer disease (because of the possibility of upper gastro-intestinal haemorrhage).
Care should be exercised when Carbidopa/Levodopa tablet is administered to patients with a history of myocardial infarction who have residual atrial nodal, or ventricular arrhythmias. Cardiac function should be monitored with particular care in such patients during the period of initial dosage adjustment.
Levodopa has been associated with somnolence and episodes of sudden sleep onset. Sudden onset of sleep during daily activities, in some cases without awareness or warning signs, has been reported very rarely. Patients must be informed of this and advised to exercise caution while driving or operating machines during treatment with levodopa. Patients who have experienced somnolence and/or an episode of sudden sleep onset must refrain from driving or operating machines. Furthermore, a reduction of dosage or termination of therapy may be considered.
All patients should be monitored carefully for the development of mental changes, depression with suicidal tendencies, and other serious antisocial behaviour. Patients with current psychoses should be treated with caution.
Dyskinesias may occur in patients previously treated with levodopa alone because carbidopa permits more levodopa to reach the brain and, thus, more dopamine to be formed. The occurrence of dyskinesias may require dosage reduction.
As with levodopa, Carbidopa/Levodopa tablet may cause involuntary movements and mental disturbances. Patients with a history of severe involuntary movements or psychotic episodes when treated with levodopa alone should be observed carefully when Carbidopa/Levodopa tablet is substituted. These reactions are thought to be due to increased brain dopamine following administration of levodopa, and use of Carbidopa/Levodopa tablet may cause a recurrence. A syndrome resembling the neuroleptic malignant syndrome including muscular rigidity, elevated body temperature, mental changes and increased serum creatine phosphokinase has been reported with the abrupt withdrawal of antiparkinsonian agents. Therefore, any abrupt dosage reduction or withdrawal of Carbidopa/Levodopa tablets should be carefully observed, particularly in patients who are also receiving neuroleptics.
Concomitant administration of psycho-active drugs such as phenothiazines or butyrophenones should be carried out with caution, and the patient carefully observed for loss of antiparkinsonian effect. Patients with a history of convulsions should be treated with caution.
As with levodopa, periodic evaluation of hepatic, haematopoetic, cardiovascular and renal function are recommended during extended therapy.
Patients with chronic wide-angle glaucoma may be treated cautiously with Carbidopa/Levodopa tablets, provided the intra-ocular pressure is well controlled and the patient monitored carefully for changes in intra-ocular pressure during therapy.
If general anaesthesia is required, therapy with Carbidopa/Levodopa tablets may be continued for as long as the patient is permitted to take fluids and medication by mouth. If therapy has to be stopped temporarily, Carbidopa/Levodopa tablet may be restarted as soon as oral medication can be taken at the same daily dosage as before.
Epidemiological studies have shown that patients with Parkinson's disease have a higher risk of developing melanoma than the general population (approximately 2-6-fold higher). It is unclear whether the increased risk observed was due to Parkinson's disease, or other factors such as drugs used to treat Parkinson's disease. Therefore, patients and providers are advised to monitor for melanomas on a regular basis when using Carbidopa/Levodopa tablets for any indication. Ideally, periodic skin examinations should be performed by appropriately qualified individuals (e.g., dermatologists).
Treatment with carbidopa/levodopa can lead to vitamin B6 deficiency, which may increase the risk of seizures, particularly in patients receiving higher doses, and/or those with poor nutritional status. Monitoring of pyridoxine (vitamin B6) levels and vitamin B6 supplementation should be considered in patients receiving high-dose carbidopa/levodopa and those presenting with clinical manifestations suggestive of vitamin B6 deficiency.
Laboratory Tests
Commonly, levels of blood urea nitrogen, creatinine, and uric acid are lower during administration of Carbidopa/Levodopa tablet than with levodopa. Transient abnormalities include elevated levels of blood urea, AST (SGOT), ALT (SGPT), LDH, bilirubin, and alkaline phosphatase.
Decreased haemoglobin, haematocrit, elevated serum glucose and white blood cells, bacteria and blood in the urine have been reported.
Positive Coombs' tests have been reported, both with Carbidopa/Levodopa tablet and levodopa alone.
Carbidopa/Levodopa tablet may cause a false positive result when a dipstick is used to test for urinary ketone; and this reaction is not altered by boiling the urine. The use of glucose oxidase methods may give false negative results for glycosuria.
Dopamine Dysregulation Syndrome (DDS) is an addictive disorder resulting in excessive use of the product seen in some patients treated with carbidopa/ levodopa. Before initiation of treatment, patients and caregivers should be warned of the potential risk of developing DDS (see also section 4.8).
Impulse control disorders
Patients should be regularly monitored for the development of impulse control disorders. Patients and carers should be made aware that behavioural symptoms of impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa including Carbidopa/Levodopa tablet. Review of treatment is recommended if such symptoms develop.
4.5 Interaction with other medicinal products and other forms of interaction
Caution should be exercised when the following drugs are administered concomitantly with Carbidopa/Levodopa tablet.
Antihypertensive agents
Postural hypotension can occur when Carbidopa/Levodopa tablet is added to the treatment of patients already receiving antihypertensive drugs. Dosage adjustment of the antihypertensive agent may be required.
Antidepressants
Rarely, reactions including hypertension and dyskinesia have been reported with the concomitant use of tricyclic antidepressants (see first paragraph of section 4.3 'Contraindications' for patients receiving MAOIs).
Anticholinergics
Anticholinergics may affect the absorption and thus the patient's response.
Iron
Studies demonstrate a decrease in the bioavailability of carbidopa and/or levodopa when it is ingested with ferrous sulphate or ferrous gluconate.
Other drugs
To date there has been no indication of interactions that would preclude concurrent use of standard antiparkinsonian drugs.
Dopamine D2 receptor antagonists (e.g. phenothiazines, butyrophenones, and risperidone) and isoniazid, may reduce the therapeutic effects of levodopa. The beneficial effects of levodopa in Parkinson's disease have been reported to be reversed by phenytoin and papaverine. Patients taking these drugs with Carbidopa/Levodopa tablet should be carefully observed for loss of therapeutic response.
Use of Carbidopa/Levodopa tablet with dopamine-depleting agents (e.g., tetrabenazine) or other drugs known to deplete monoamine stores is not recommended.
Concomitant therapy with selegiline and carbidopa-levodopa may be associated with severe orthostatic hypotension not attributable to carbidopa-levodopa alone (see section 4.3 'Contraindications').
Since levodopa competes with certain amino acids, the absorption of Carbidopa/Levodopa tablets may be impaired in some patients on a high protein diet.
The effect of simultaneous administration of antacids with Carbidopa/Levodopa tablet on the bioavailability of levodopa has not been studied.
Carbidopa/Levodopa tablets may be given to patients with Parkinson's disease and syndrome who are taking vitamin preparations that contain pyridoxine hydrochloride (Vitamin B6).
4.6 Fertility, pregnancy and lactation
Pregnancy
Although the effects of Carbidopa/Levodopa tablet on human pregnancy are unknown, both levodopa and combinations of carbidopa and levodopa have caused visceral and skeletal malformations in rabbits. Therefore, the use of Carbidopa/Levodopa tablet in women of childbearing potential requires that the anticipated benefits of the drug be weighed against possible hazards should pregnancy occur.
Breast-feeding
It is not known whether carbidopa is excreted in human milk. In a study of one nursing mother with Parkinson's disease, excretion of levodopa in human breast milk was reported. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in infants, a decision should be made whether to discontinue breast-feeding or discontinue the use of Carbidopa/Levodopa tablet, taking into account the importance of the drug to the mother.
4.7 Effects on ability to drive and use machines
Individual responses to medication may vary and certain side effects that have been reported with Carbidopa/Levodopa tablet may affect some patients' ability to drive or operate machinery. Patients treated with levodopa and presenting with somnolence and/or sudden sleep episodes must be informed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines), until such recurrent episodes and somnolence have resolved (see also section 4.4 'Special warnings and precautions for use').
4.8 Undesirable effects
Side effects that occur frequently with Carbidopa/Levodopa tablet are those due to the central neuropharmacological activity of dopamine. These reactions can usually be diminished by dosage reduction. The most common are dyskinesias including choreiform, dystonic and other involuntary movements and nausea. Muscle twitching and blepharospasm may be taken as early signs to consider dosage reduction.
Other side effects reported in clinical trials or in post-marketing experience include:
Infections and infestations: urinary tract infections (frequency: very common)
Metabolism and nutrition disorders: Vitamin B6 deficiency (frequency: common)
Body as a whole: syncope, chest pain, anorexia.
Cardiovascular: cardiac irregularities and/or palpitations, orthostatic effects including hypotensive episodes, hypertension, phlebitis.
Gastro-intestinal: vomiting, gastro-intestinal bleeding, development of duodenal ulcer, diarrhoea, dark saliva.
Hematologic: leukopenia, haemolytic and non-haemolytic anaemia, thrombocytopenia, agranulocytosis.
Hypersensitivity: angioedema, urticaria, pruritus, Henoch-Schonlein purpura.
Nervous System/Psychiatric: neuroleptic malignant syndrome (see section 4.3 'Contraindications'), bradykinetic episodes (the “on-off” phenomenon), dizziness, paraesthesia, psychotic episodes including delusions, hallucinations and paranoid ideation, depression with or without development of suicidal tendencies, dementia, dream abnormalities, agitation, confusion, increased libido. Levodopa is associated with somnolence and has been associated very rarely with excessive daytime somnolence and sudden sleep onset episodes.
Respiratory: dyspnoea.
Skin: alopecia, rash, dark sweat.
Urogenital: dark urine.
Rarely convulsions have occurred; however, a causal relationship with Carbidopa/Levodopa tablet has not been established.
Other side effects that have been reported with levodopa or levodopa/carbidopa combinations and may be potential side effects with Carbidopa/Levodopa tablet include:
Gastro-intestinal:
dyspepsia, dry mouth, bitter taste, sialorrhoea, dysphagia, bruxism, hiccups, abdominal pain and distress, constipation, flatulence, burning sensation of the tongue.
Metabolic: weight gain or loss, oedema.
Nervous System/Psychiatric: asthenia, decreased mental acuity, disorientation, ataxia, numbness, increased hand tremor, muscle cramp, trismus, activation of latent Horner's syndrome, insomnia, anxiety, euphoria, falling, gait abnormalities and Dopamine Dysregulation Syndrome.
Description of selected adverse reactions
Dopamine Dysregulation Syndrome (DDS) is an addictive disorder seen in some patients treated with carbidopa/levodopa. Affected patients show a compulsive pattern of dopaminergic drug misuse above doses adequate to control motor symptoms, which may in some cases result in severe dyskinesias (see also section 4.4).
Impulse control disorders
Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa including Carbidopa/Levodopa tablet (see section 4.4. 'Special warnings and precautions for use').
Skin: flushing, increased sweating.
Special senses: diplopia, blurred vision, dilated pupils, oculogyric crises.
Urogenital: urinary retention, urinary incontinence, priapism.
Miscellaneous:
weakness, faintness, fatigue, headache, hoarseness, malaise, hot flushes, sense of stimulation, bizarre breathing patterns, malignant melanoma (see section 4.3 'Contraindications').
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9 Overdose
Treatment
Management of acute overdosage with Carbidopa/Levodopa tablet is basically the same as management of acute overdosage with levodopa; however, pyridoxine is not effective in reversing the actions of Carbidopa/Levodopa tablet. ECG monitoring should be instituted, and the patient carefully observed for the possible development of arrhythmias; if required, appropriate anti-arrhythmic therapy should be given. The possibility that the patient may have taken other drugs as well as Carbidopa/Levodopa tablets should be taken into consideration. To date, no experience has been reported with dialysis, and hence its value in the treatment of overdosage is not known. The terminal half-life of levodopa is about two hours in the presence of carbidopa.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Anti-Parkinson drugs
ATC code: N04BA02
Mechanism of action
Levodopa is a precursor of dopamine and is given as replacement therapy in Parkinson's disease.
Carbidopa is a peripheral dopa decarboxylase inhibitor. It prevents metabolism of levodopa to dopamine in the peripheral circulation, ensuring that a higher proportion of the dose reaches the brain, where dopamine acts. A lower dose of levodopa can be used, reducing the incidence and severity of side effects.
Pharmacodynamics effects
Carbidopa/Levodopa tablet is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. It is frequently helpful in the management of tremor, dysphagia, sialorrhea, and postural instability associated with Parkinson’s disease and syndrome.
When response to levodopa alone is irregular, and signs and symptoms of Parkinson's disease are not controlled evenly throughout the day, substitution of Carbidopa/Levodopa tablet usually reduces fluctuations in response. By reducing some of the adverse reactions produced by levodopa alone, Carbidopa/Levodopa tablets permit more patients to obtain adequate relief from the symptoms of Parkinson's disease.
5.2 Pharmacokinetic properties
Absorption
Following oral dosing levodopa, in the absence of decarboxylase inhibitor, is rapidly but variably absorbed from the gastro-intestinal tract. It has a plasma half-life of about 1 hour and is mainly converted by decarboxylation to dopamine, a proportion of which is converted to noradrenaline. Up to 30 % is converted to 3-O-methyldopa which has a half-life of9 to 22 hours. About 80 % of levodopa is excreted in the urine within 24 hours mainly as homovanillic acid and dihydroxyphenyl lactic acid. Less than 1% is excreted unchanged.
Once in the circulation it competes with other neutral amino acids for transport across the blood brain barrier. Once it has entered the striatal neurones it is decarboxylated to dopamine, stored and released from presynaptic neurones. Because levodopa is so rapidly decarboxylated in the gastro-intestinal tract and the liver, very little unchanged drug is available for transport into the brain. The peripheral decarboxylation reduces the therapeutic effectiveness of levodopa but is responsible for many of its side effects. For this reason, levodopa is usually administered together with a peripheral decarboxylase inhibitor such as carbidopa, so that lower doses may be given to achieve the same therapeutic effect.
Carbidopa in the absence of levodopa, is rapidly but incompletely absorbed from the gastrointestinal tract following oral dosing. Following an oral dose approximately 50% is recorded in the urine, with about 3% of this as unchanged drug. It does not cross the blood brain barrier but crosses the placenta and is excreted in breast milk. Turnover of the drug is rapid, and virtually all unchanged drug appears in the urine within 7 hours.
Carbidopa inhibits the peripheral decarboxylation of levodopa to dopamine but as it does not cross the blood brain barrier, effective brain levels of dopamine get produced with lower levels of levodopa therapy reducing the peripheral side effects, noticeably nausea and vomiting and cardiac arrhythmias.
5.3 Preclinical safety data
Carbidopa/Levodopa tablets are well established in medical use. Preclinical data is broadly consistent with clinical experience. (For reproductive toxicity, see section 4.6 'Fertility, pregnancy and Lactation'.)
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Cellulose microcrystalline (grade-101)
Starch, pregelatinized (maize starch)
Crospovidone (type B)
Indigo Carmine (FD&C Blue No.2) Aluminium lake (E 132) Hydroxypropyl cellulose (100 cps)
Magnesium stearate
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
3 years
6.4 Special precautions for storage
This medicinal product does not require any special storage conditions.
6.5 Nature and contents of container
This medicine is available in triple laminated cold form (Alu-Alu) blister pack and also available in white opaque round HDPE container closed with white opaque polypropylene closure with wad having induction sealing liner. Pack sizes:
Blister packs: 100 tablets.
HDPE packs: 50, 100, 250 and 500 tablets.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7 MARKETING AUTHORISATION HOLDER
Milpharm Limited
1 Roundwood Avenue,
Stockley Park,
Uxbridge,
UB11 1AF
United Kingdom
8 MARKETING AUTHORISATION NUMBER(S)
PL 16363/0879
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
15/07/2026
10 DATE OF REVISION OF THE TEXT
05/10/2026